CAJ | 학술논문

目的评价地氯雷他定治疗变应性鼻炎的疗效及其安全性。方法计算机检索 SCI、Pubmed、Elsevier、Cochrane图书馆、万方、中国知网中关于地氯雷他定治疗变应性鼻炎的随机对照试验，同时追索纳入文献的参考文献。检索年限均从建库检索到2012年12月。由两名评价员独立筛查文献，采用Jadad修订版的量表对纳入的文献进行质量评价，并提取资料，对符合质量标准的随机对照试验（ RCT）进行Meta分析，比较地氯雷他定组和安慰剂组总的症状评分、总的鼻部症状评分、总的非鼻部症状评分、单一鼻部症状评分、生活质量评价和安全性评估。统计学分析采用RevMan 5.0软件。结果共纳入9个RCT。地氯雷他定（5 mg/d）可有效改善变应性鼻炎患者的症状，可降低患者总的症状评分、总的鼻部症状评分、总的非鼻部症状评分及部分单一的鼻部症状评分。地氯雷他定可有效提高生活质量，降低患者总的生活质量评分（P均＜0.05）。地氯雷他定的不良反应发生率与安慰剂组相似，不良反应发生差异无统计学意义（ P＞0.05）。结论地氯雷他定（5 mg/d）可以有效缓解患者的症状，改善患者的生活质量，且不良反应发生率与对照组相近。
목적평개지록뢰타정치료변응성비염적료효급기안전성。방법계산궤검색 SCI、Pubmed、Elsevier、Cochrane도서관、만방、중국지망중관우지록뢰타정치료변응성비염적수궤대조시험，동시추색납입문헌적삼고문헌。검색년한균종건고검색도2012년12월。유량명평개원독립사사문헌，채용Jadad수정판적량표대납입적문헌진행질량평개，병제취자료，대부합질량표준적수궤대조시험（ RCT）진행Meta분석，비교지록뢰타정조화안위제조총적증상평분、총적비부증상평분、총적비비부증상평분、단일비부증상평분、생활질량평개화안전성평고。통계학분석채용RevMan 5.0연건。결과공납입9개RCT。지록뢰타정（5 mg/d）가유효개선변응성비염환자적증상，가강저환자총적증상평분、총적비부증상평분、총적비비부증상평분급부분단일적비부증상평분。지록뢰타정가유효제고생활질량，강저환자총적생활질량평분（P균＜0.05）。지록뢰타정적불량반응발생솔여안위제조상사，불량반응발생차이무통계학의의（ P＞0.05）。결론지록뢰타정（5 mg/d）가이유효완해환자적증상，개선환자적생활질량，차불량반응발생솔여대조조상근。
the randomized controlled trials ( RCTs ) of the efficacy and safety of desloratadine in subjects with allergic rhinitis from the date of establishment to December 2012 .The bibliographies of the included studies were searched too .Two independent researchers evaluated the included studies using jadad revised edition of the scale .The RCTs which conformed to the quality standard would be resorted to Meta analysis .The study had been analyzed several aspects including the total symptom scores ,the total nasal symptom scores ,the total nonnasal symptom scores ,the single nasal symptom scores , the quality of life , safety and eosinophil counts between the desloratadine group and the placebo group respectively .The RevMan 5.0 was used to perform statistical analysis .Results A total of 9 trials were included in this study .The treatment of desloratadine was valid to improve the symptom and the quality of life in the allergic rhinitis patients .The total symptom scores ,the total nasal symptom scores ,the total nonnasal symptom scores , the single nasal symptom scores and the total RQLQ in group treated with desloratadine (5 mg/d) showed significant difference ( P<0.05 ) when compared with controls .The side effects incidence in the desloratadine group was similar to the placebo group ,which did not show significant difference ( P>0.05 ) in two groups .Conclusion The current evidence shows that desloratadine (5 mg/d) can efficiently release the symptom and improve the quality of life .The side effects incidence is very similar to the controls .